Blood test guides new attack on lung cancer return
NCT ID NCT04585477
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study uses a blood test to detect tiny amounts of cancer DNA left after standard treatment for early-stage non-small cell lung cancer. People whose blood shows this leftover cancer are at higher risk of the cancer coming back. The study tests whether the drug durvalumab can reduce these cancer DNA levels. About 80 adults with stage I to III lung cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.